|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...133134135136137138139140141142143...156157» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: FasT: Observation of Treatment With Certolizumab Pegol in Daily Practice (clinicaltrials.gov) - Sep 27, 2012
P=N/A, N=1117, Active, not recruiting, Sponsor: UCB, Inc.
Enrolling by invitation --> Active, not recruiting
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) (clinicaltrials.gov) - Sep 27, 2012
P4, N=91, Completed, Sponsor: Genentech
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||| Benlysta (belimumab) / GSK
Enrollment open: A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Sep 26, 2012
P4, N=80, Recruiting, Sponsor: Human Genome Sciences Inc., a GSK Company
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Review, Adherence: READER: An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=230, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- || Betaseron (IFN-?-1b) / Bayer
Enrollment change, Immunomodulating: Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=252, Completed, Sponsor: Bayer
Active, not recruiting --> Completed N=400 --> 252
- ||| Betaseron (IFN-?-1b) / Bayer
Trial completion, Immunomodulating: Depression and Fatigue in MS Patients Treated With Betaferon. (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=252, Completed, Sponsor: Bayer
N=400 --> 252 Recruiting --> Completed
- || entecavir / Generic mfg.
New P3 trial: Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα (clinicaltrials.gov) - Sep 25, 2012
P3, N=128, Recruiting, Sponsor: Seoul National University Hospital
- ||| Trial completion: Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=103, Completed, Sponsor: Questcor Pharmaceuticals, Inc.
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: CD-DIET: Celiac Disease and Diabetes- Dietary Intervention and Evaluation Trial (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=200, Recruiting, Sponsor: The Hospital for Sick Children
Recruiting --> Completed Active, not recruiting --> Recruiting
- Trial completion: MD2Me - Texting to Promote Chronic Disease Management (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=81, Completed, Sponsor: Huang, Jeannie, M.D.
Active, not recruiting --> Recruiting Enrolling by invitation --> Completed
- cyclosporin A microemulsion / Generic mfg.
New P2 trial: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - Sep 24, 2012
P2, N=30, Recruiting, Sponsor: Charite University, Berlin, Germany
- ||||||| omega-3 ethylester concentrate / Generic mfg.
Trial completion: IgAN: Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy (clinicaltrials.gov) - Sep 24, 2012
P3, N=152, Completed, Sponsor: Kuhnil Pharmaceutical Co., Ltd.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Enrollment change: A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia (clinicaltrials.gov) - Sep 24, 2012
P2, N=10, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed N=20 --> 10
- Victoza (liraglutide) / Novo Nordisk
Enrollment open: Liraglutide in Type 1 Diabetes (clinicaltrials.gov) - Sep 24, 2012
P4, N=100, Recruiting, Sponsor: Steno Diabetes Center
N=20 --> 10 Not yet recruiting --> Recruiting
- Promacta (eltrombopag) / Novartis
Enrollment open: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (clinicaltrials.gov) - Sep 24, 2012
P2, N=26, Recruiting, Sponsor: Fondazione Progetto Ematologia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P4 trial: A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (clinicaltrials.gov) - Sep 23, 2012
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Clinical data, Enrollment closed, Combination therapy: BREVACTA: A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 23, 2012
P3, N=656, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: MAINTAIN: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice (clinicaltrials.gov) - Sep 23, 2012
P4, N=780, Completed, Sponsor: Pfizer
- Enrollment open: A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 23, 2012
P1, N=40, Recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| New P4 trial: Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents (clinicaltrials.gov) - Sep 20, 2012
P4, N=144, Recruiting, Sponsor: Pfizer
- LENZ (lenzilumab) / Humanigen
Trial termination: Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis (clinicaltrials.gov) - Sep 20, 2012
P2, N=9, Terminated, Sponsor: KaloBios Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated; Program refocus
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial termination: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=7, Terminated, Sponsor: Joslin Diabetes Center
Completed --> Terminated; Program refocus Recruiting --> Terminated; Treatment differences not detected with 7 point fingerstick monitoring
- LENZ (lenzilumab) / Humanigen
Trial initiation date: Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis (clinicaltrials.gov) - Sep 20, 2012
P2, N=9, Terminated, Sponsor: KaloBios Pharmaceuticals
Recruiting --> Terminated; Treatment differences not detected with 7 point fingerstick monitoring Initiation date: Oct 2009 --> Jan 2010
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=7, Terminated, Sponsor: Joslin Diabetes Center
Initiation date: Oct 2009 --> Jan 2010 N=40 --> 7
- vildagliptin / Generic mfg.
Trial completion: Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes (clinicaltrials.gov) - Sep 20, 2012
P4, N=28, Completed, Sponsor: Lund University
N=40 --> 7 Recruiting --> Completed
- |||||||||| Plivensia (sirukumab) / J&J
New P3 trial, Monotherapy: A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine (clinicaltrials.gov) - Sep 19, 2012
P3, N=122, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
- ||||| Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed: An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 19, 2012
P3, N=135, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial: EDITION JP I: Comparison of a New Formulation of Insulin Glargine With Lantus (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Active, not recruiting, Sponsor: Sanofi
- | adomeglivant (LY2409021) / Eli Lilly
Trial completion: Study of LY2409021 in Participants With Type 1 Diabetes (clinicaltrials.gov) - Sep 19, 2012
P1, N=30, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. (clinicaltrials.gov) - Sep 18, 2012
P3, N=194, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed N=194194 --> 194
- | ligelizumab (QGE 031) / Novartis
New P2 trial: Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment (clinicaltrials.gov) - Sep 18, 2012
P2, N=42, Recruiting, Sponsor: Novartis Pharmaceuticals
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab in the Treatment of Patients With Bullous Pemphigoid (clinicaltrials.gov) - Sep 18, 2012
P1/2, N=8, Completed, Sponsor: Duke University
N=194194 --> 194 Active, not recruiting --> Completed
- Enrollment change: Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting (clinicaltrials.gov) - Sep 18, 2012
P1, N=20, Completed, Sponsor: Animas Corporation
Active, not recruiting --> Completed N=30 --> 20
- NN9828 / Novo Nordisk
New P1 trial: An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Sep 18, 2012
P1, N=10, Terminated, Sponsor: Novo Nordisk A/S
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Sep 18, 2012
P4, N=618, Recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 20 Not yet recruiting --> Recruiting
- | Trial completion: Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting (clinicaltrials.gov) - Sep 18, 2012
P1, N=20, Completed, Sponsor: Animas Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION) (clinicaltrials.gov) - Sep 18, 2012
P3, N=121, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Effect of Dietary Fat on Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=10, Completed, Sponsor: Joslin Diabetes Center
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Symlin (pramlintide) / AstraZeneca
Enrollment change: Pramlintide in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=10, Completed, Sponsor: University of Colorado, Denver
Enrolling by invitation --> Completed N=60 --> 10
- ||||| ultra-rapid-acting recombinant human insulin (BIOD-123) / Ipsen
New P2 trial: A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog (clinicaltrials.gov) - Sep 16, 2012
P2, N=130, Active, not recruiting, Sponsor: Biodel
- ||| Venclexta (venetoclax) / Roche, AbbVie
New P1 trial: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Sep 16, 2012
P1, N=88, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- | solcitinib (GSK2586184) / Galapagos
New P1 trial: JAK116439: A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender (clinicaltrials.gov) - Sep 16, 2012
P1, N=19, Completed, Sponsor: GlaxoSmithKline
- Trial completion: Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=21, Completed, Sponsor: University of Colorado, Denver
N=60 --> 10 Recruiting --> Completed
- Symlin (pramlintide) / AstraZeneca
Trial completion: Pramlintide in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=10, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed N=2500 --> 4500
- trichuris suis ova (CNDO-201) / Fortress
Enrollment open: TRIOMS: Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome (clinicaltrials.gov) - Sep 13, 2012
P2, N=50, Recruiting, Sponsor: Charite University, Berlin, Germany
N=2500 --> 4500 Not yet recruiting --> Recruiting
- Enrollment closed: Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=2000, Active, not recruiting, Sponsor: Fondazione Italiana Sclerosi Multipla
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Sep 12, 2012
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=120 --> 42
- || Avonex (recombinant IFN-β-1a) / Biogen
Enrollment closed, HEOR, Adherence: Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™. (clinicaltrials.gov) - Sep 12, 2012
P=N/A, N=280, Active, not recruiting, Sponsor: Biogen Idec
N=120 --> 42 Recruiting --> Active, not recruiting
- ||||||| Ilaris (canakinumab) / Novartis
Trial completion: ?-SPECIFIC 2: Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (clinicaltrials.gov) - Sep 12, 2012
P3, N=177, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed